Research analysts at Guggenheim started coverage on shares of Cybin (NYSE:CYBN - Get Free Report) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $35.00 price target on the stock. Guggenheim's price objective points to a potential upside of 376.84% from the company's previous close.
A number of other brokerages have also weighed in on CYBN. Canaccord Genuity Group lowered their price objective on Cybin from $86.00 to $73.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. HC Wainwright decreased their price target on shares of Cybin from $190.00 to $150.00 and set a "buy" rating for the company in a research report on Thursday, February 13th.
Get Our Latest Stock Analysis on CYBN
Shares of Cybin stock opened at $7.34 on Thursday. Cybin has a 1-year low of $6.50 and a 1-year high of $19.85. The firm has a market capitalization of $157.64 million, a P/E ratio of -1.68 and a beta of 0.50. The firm's 50-day simple moving average is $9.08.
Institutional investors and hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new position in Cybin in the fourth quarter worth $46,000. Marshall Wace LLP acquired a new position in shares of Cybin in the 4th quarter valued at about $94,000. Cowa LLC bought a new stake in shares of Cybin during the 4th quarter valued at about $115,000. Essential Planning LLC. acquired a new stake in Cybin during the fourth quarter worth about $138,000. Finally, Diametric Capital LP acquired a new stake in Cybin during the fourth quarter worth about $157,000. 17.94% of the stock is owned by institutional investors and hedge funds.
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.